Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: Remission of refractory anemia following mycophenolate mofetil

J. T. Lin, W. S. Wang, C. C. Yen, T. J. Chiou, J. H. Liu, L. T. Hsiao, M. H. Yang, T. C. Chao, C. J. Tai, P. M. Chen

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Autoimmune hemolytic anemia (AIHA) rarely occurs in myelodysplastic syndrome (MDS). A 36-year-old Asian female was diagnosed with MDS (refractory cytopenia with multilineage dysplasia, RCMD) and complicated by AIHA 7 months later. Secondary myelofibrosis developed at the same time. Steroid therapy was ineffective and cyclosporin A (CsA) was discontinued due to its neurotoxicity with the development of leukoencephalopathy. However, the patient achieved a good hematological response after the use of mycophenolate mofetil (MMF, CellCept) with a dose of 1 g/day and prednisolone (15 mg/day). Prednisolone was tapered off over the next 3 weeks. The patient did not require any blood support 4 weeks after the use of MMF and has been hematologically stable for 4 months. To our knowledge, this is the first report of using MMF in treating MDS complicated by AIHA. MMF might be considered as a salvage therapy for patients with refractory anemia complicated by AIHA.

Original languageEnglish
Pages (from-to)723-726
Number of pages4
JournalAnnals of Hematology
Volume81
Issue number12
DOIs
Publication statusPublished - Dec 2002
Externally publishedYes

Keywords

  • Autoimmune hemolytic anemia
  • Mycophenolate mofetil
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: Remission of refractory anemia following mycophenolate mofetil'. Together they form a unique fingerprint.

Cite this